In PACIFIC 4, a placebo-controlled, phase III trial, patients with T1–3 N0 M0 unresected NSCLC are being randomised to receive durvalumab or placebo every 4 weeks for up to 26 weeks with concurrent SBRT,67 a sub-cohort of patients with EGFR mutations will receive osimertinib instead of durvalumab. Here, EGFR is linked to non-small cell lung carcinoma.